Episode: 87 - Jack Elands on How Novel ADC Payloads Could Improve Cancer Care GUEST: Jack Elands, Ph.D., Founder and CEO, Adcytherix
July 14, 2026 | Most ADCs today lean on the same Topo-1 payloads—and resistance is catching up. Jack Elands, Ph.D., founder and CEO of Adcytherix, speaks with host Rakesh Dixit, Ph.D. about what “next-generation ADCs” should mean if we care about patients, not just pipeline counts. Their conversation gets specific about where differentiation comes from: novel payloads with new mechanisms of action, better therapeutic index choices, and smarter design decisions that reduce the toxicities that ...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Chain: Protein Engineering Podcast
Episode: 89 - James E. Crowe, Jr. on AHEAD 100, a New Strategy for Preparing for the Next Pandemic
Episode: 88 - Janice Reichert on the Evolution of Antibody Therapeutics
Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D
Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating
Get summaries like this every morning.
Free AI-powered recaps of The Chain: Protein Engineering Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.